Background: Bevacizumab (BV) is widely used in chemotherapy for metastatic colorectal
cancer (mCRC). Although specific adverse events have been observed, their risk factors …

Background Bevacizumab (BV) prolongs overall survival and progression-free survival
when combined with standard chemotherapy for metastatic colorectal cancer (mCRC) …

Purpose: To determine the clinical features of bevacizumab-associated toxicities in
metastatic colorectal cancer (MCRC) patients. Methods: The medical records of 60 patients …

Objective After approval of bevacizumab in Japan, post-marketing surveillance studies
reported on safety. However, few reports have shown the efficacy of bevacizumab as used in …

Objective: Bevacizumab has been increasingly used in combination chemotherapy for the
treatment of metastatic or recurrent colorectal cancer. The aim of this report is to underline …

3536 Background: Bevacizumab (BV) prolongs overall survival and progression-free
survival when added to standard chemotherapy for patients with metastatic colorectal cancer …

Abstract Background Bevacizumab (Avastin®) was approved in Japan in April 2007 for
patients with advanced or metastatic colorectal cancer. To address the limited clinical …

Objective: An increased risk of serious adverse effects related to bevacizumab has been
observed in many Western studies for metastatic colorectal cancer. To evaluate the safety of …

Background There has so far been little information on the clinical effect of bevacizumab
against colorectal cancer in Japan. Hence, this study was conducted to retrospectively …

Background/Aim: Bevacizumab-based chemotherapy is the standard treatment for
metastatic colorectal cancer (mCRC) but has several specific adverse events. The …